CTOs on the Move

CareCentrix

www.carecentrix.com

 
CareCentrix is a leader in managing care to the home. Headquartered in Hartford, Conn., CareCentrix connects patients with the care they need at home, through a national network of over 8,000 credentialed provider locations providers, with customer care centers located across the United States. CareCentrix provides optimal access to quality home care for more than 23 million lives by connecting providers with patients and helping them navigate the complex home care system. CareCentrix`s extensive range of services provides support and coordination for patients and their families in every step of the healing process, including home health, durable medical equipment (DME), ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Jason Frank
Senior Director - Technology Infrastructure Profile
Matthew Mudry
Area Vice President - Information Security and Architecture Profile

Similar Companies

Charlotte's Optical Co Inc

Charlotte's Optical Co Inc is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Big Health

Our purpose is to help millions back to good mental health. We do this by creating fully-automated and highly personalized digital therapeutics for mental health.

Trivani

Trivani is a Springville, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OmniSYS-LLC

OmniSYS-LLC is a Greenville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.